- Critical frozen logistics solution supports shipments of
mouse mutant lines to EMMA clients in more than 40 different
countries with a focus on Europe
and Northern America
LAKE FOREST, California,
April 1, 2014 /PRNewswire/ --
Cryoport, Inc. (OTCBB: CYRX), the only end-to-end cryogenic
logistics solutions provider, today announced that it has entered
into an agreement with the European Mouse Mutant Archive("EMMA"), a
part of INFRAFRONTIER, the European Research Infrastructure for
phenotyping and archiving of model mammalian genomes. Under the
agreement, the partners of the EMMA and their global clients will
be able to ship frozen biomaterials using Cryoport's purpose-built
cryogenic logistics solutions.
Photo -
http://photos.prnewswire.com/prnh/20140401/NY95107LOGO
Cryoport's solutions include dry vapor liquid nitrogen Cryoport
Express® Shippers; the CryoportalTM, a robust,
cloud-based logistics management platform; and cold chain logistics
expertise that provides around-the-clock client support. Cryoport's
solutions substantially reduce "process nuisance" as well as the
cost of ordering, using, and temporarily storing cell-based
biologic products at validated cryogenic temperatures. At the core,
Cryoport's solutions eliminate the need for hazardous dry ice
and/or capital investments in cryogenic containers; significantly
reduce the risk of degradation of shipped biomaterials; tracks
shipments throughout the process with intervention capability in
time of need; and provide vital custody and condition
information.
EMMA, a non-profit repository for the collection, archiving (via
cryopreservation) and distribution of relevant mutant mouse strains
essential for basic biomedical research, provides its mouse mutant
resources to biomedical researchers worldwide and currently holds
about 4,400 mutant mouse lines. Since its inception in 2000, the
number of mutant mouse strains submitted to EMMA and the number of
requests has steadily increased. To date, EMMA has shipped
approximately 3,500 mouse mutant lines to clients in more than 40
different countries with a focus on Europe and Northern America.
Prof. Martin Hrabe de Angelis,
EMMA Director, stated, "Cryoport's solutions will allow us to
overcome the challenge of biomaterial degradation during shipment
around the world, as it ensures a constant cryogenic environment.
As a result, this advanced solution will ensure our customers
receive material for their research that meets our stringent
guidelines."
Dr. Martin D. Fray, MRC Harwell,
stated, "In our experience, Cryoport offers an excellent solution
that we can rely on when distributing frozen embryos and sperm
around the world. Using Cryoport's turn-key cryogenic solution
instead of our own equipment has streamlined our operation and
introduced some real efficiencies."
"We are excited to have EMMA implement our cryogenic logistics
solutions to support shipments of biomaterials to their partners
around the world, including the many well-known academic
facilities," stated Jerrell Shelton,
Cryoport's Chief Executive Officer. "Through this agreement with
EMMA, Cryoport will be improving its foothold in the European
market with exposure to a broad customer base."
The European Mouse Mutant Archive ("EMMA")
The EMMA
is a non-profit repository for the collection, archiving (via
cryopreservation) and distribution of relevant mutant mouse strains
essential for basic biomedical research. The laboratory mouse is
one of the most important mammalian models for studying genetic and
multi-factorial diseases in man. The comprehensive physical and
data resources of EMMA support basic biomedical and preclinical
research, and the available research tools and mouse models of
human disease offer the opportunity to develop a better
understanding of molecular disease mechanisms and may provide the
foundation for the development of diagnostic, prognostic and
therapeutic strategies. EMMA is supported by the partner
institutions, national research programs and by the EC's FP7
Capacities Specific Program
About INFRAFRONTIER
INFRAFRONTIER is the European
Research Infrastructure for phenotyping and archiving of model
mammalian genomes. The INFRAFRONTIER Research Infrastructure
provides access to first-class tools and data for biomedical
research, and thereby contributes to improving the understanding of
gene function in human health and disease using the mouse
model.
The core services of INFRAFRONTIER comprise the systemic
phenotyping of mouse mutants in the participating mouse clinics,
and the archiving and distribution of mouse mutant lines by the
European Mouse Mutant Archive (EMMA). In addition, INFRAFRONTIER
provides specialized services such as the generation of germ-free
mice (axenic service) and training in state of the art
cryopreservation and phenotyping technologies.
The INFRAFRONTIER GmbH coordinates the transnational activities
of the national partners that together form the European
INFRAFRONTIER Research Infrastructure.
https://www.infrafrontier.eu/.
About Cryoport, Inc.
Cryoport provides leading edge
frozen logistics solutions to the life sciences industry through
the combination of purpose-built proprietary packaging, information
technology and specialized cold chain logistics expertise. Its
competencies range from skilled, total turnkey management of the
entire life sciences cold chain logistics process to complex total
management solutions for outsourced cold chain logistics.
Its packaging, built around its Cryoport Express® liquid
nitrogen dry vapor shippers, is validated to maintain a constant
-150°C temperature for a 10-plus day dynamic shipment duration. Its
information technology boast a Cryoportal™ Logistics Management
Platform which manages the entire shipment process, including
initial order input, document preparation, customs clearance,
integrator/courier management, shipment tracking, issue resolution,
and delivery. Cryoport uses recyclable and reusable components
providing an environmentally friendly solution. Cryoport solutions
can record the "chain of condition" and "chain of custody" for
shipments thereby meeting the exacting requirements for scientific
work and for regulatory purposes. For more information, visit
www.cryoport.com.
Forward Looking Statements
Statements in this news
release which are not purely historical, including statements
regarding Cryoport, Inc.'s intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the company's actual results could differ materially
from those in any such forward-looking statements. Factors that
could cause actual results to differ materially include, but are
not limited to, risks and uncertainties associated with the effect
of changing economic conditions, trends in the products markets,
variations in the company's cash flow, market acceptance risks, and
technical development risks. The company's business could be
affected by a number of other factors, including the risk factors
listed from time to time in the company's SEC reports including,
but not limited to, the annual report on Form 10-K for the year
ended March 31, 2013. The company
cautions investors not to place undue reliance on the
forward-looking statements contained in this press release.
Cryoport, Inc. disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
Cryoport Investor Contacts:
Todd Fromer / Garth Russell
tfromer@kcsa.com / grussell@kcsa.com
P: 1 212-682-6300